MYCO.F Share Price Performance
US$0.0059
-0.00 (-35.71%)
Price US$0.0059
Share PriceUS$0.0059
MYCO.F Community Narratives
There are no narratives available yet.
Recent MYCO.F News & Updates
No updates
Mydecine Innovations Group Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.0036
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -45.9%
Mydecine Innovations Group Inc. Competitors
About MYCO.F
- Founded
- 2013
- Employees
- n/a
- CEO
- WebsiteView website
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Mydecine Innovations Group Inc. was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 8.1%
- 1 Year: 23.0%
- Year to Date: 10.4%
The Materials sector gained 6.0% while the market remained flat over the last week. As for the longer term, the market has risen 23% in the past 12 months. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading